Enterprise Value
745.1M
Cash
758.5M
Avg Qtr Burn
-35.92M
Short % of Float
9.04%
Insider Ownership
18.03%
Institutional Own.
75.04%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
obe-cel (AUTO1) (CD19) Details Acute lymphoblastic leukemia, Cancer, Blood cancer | PDUFA Approval decision | |
AUTO4 Details Peripheral T cell cancer | Phase 1/2 Update | |
obe-cel (AUTO1) (CD19) Details Systemic lupus erythematosus, Autoimmune disease | Phase 1 Data readout | |
AUTO8 (BMCA & CD19) Details Multiple myeloma | Phase 1 Data readout | |
AUTO6NG Details Solid tumor/s, Neuroblastoma | Phase 1 Update | |
AUTO1/22 (CD19 & CD22) Details Acute lymphoblastic leukemia, Cancer, Leukemia | Phase 1 Update | |
obe-cel (AUTO1) (CD19) Details Lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Cancer, Leukemia | Phase 1 Update | |
obe-cel (AUTO1) (CD19) Details Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas | Phase 1 Update | |
AUTO5 Details T-cell lymphoma | Phase 1 Initiation | |
AUTO3 (CD19, CD22) Details Lymphoma, Diffuse large B cell lymphoma, Cancer | Failed Discontinued |